Sildenafil (Generic) vs Alprostadil (Caverject/MUSE): Long-Term Durability of Response

What the Landmark Trials Say About Durability

Durability of response is the clinically meaningful question that goes beyond single-dose efficacy. Both sildenafil and alprostadil have strong short-term data, but their long-term trajectories diverge considerably once real-world adherence is factored in.

Sildenafil: The Goldstein 1998 NEJM Trial

The key registration trial by Goldstein et al. (N=861 men across 21 sites) published in the New England Journal of Medicine established sildenafil's durability profile [1]. At 24 weeks, sildenafil 100 mg produced successful intercourse in 69% of attempts versus 22% with placebo (P<0.001). International Index of Erectile Function (IIEF) scores improved by a mean of 7.0 points on the erectile function domain in the 100 mg group. The trial also showed dose-dependent responses at 25 mg and 50 mg, confirming flexible titration over time rather than dose escalation to maintain effect.

Tachyphylaxis, the progressive loss of drug response over repeated use, has not been demonstrated with sildenafil in controlled data. Open-label extension data from multiple PDE5 inhibitor programs suggest that men who respond at 6 months continue to respond at 24 months at similar rates, provided underlying vascular disease does not progress.

Alprostadil: The Linet 1996 NEJM Trial

The landmark intracavernosal alprostadil trial by Linet and Ogrinc (N=296 men, 12-week randomized phase plus 18-month open extension) reported that 87% of injections produced erections sufficient for intercourse in office testing [2]. At-home success rates were lower, at approximately 74% per injection across the extension period.

Long-term adherence data from that same extension are more sobering. By 18 months, a meaningful fraction of men had discontinued. Reasons cited included penile pain (37% of active users reported at least one painful episode), the psychological burden of self-injection, and partner reluctance.

Why Dropout Rates Matter More Than Peak Efficacy

Peak per-dose efficacy favors alprostadil injection (87% vs. ~69% for sildenafil 100 mg). But durability as a real-world metric must account for who stays on the drug. Observational data from urology practices suggest that 12-month continuation rates are approximately 55 to 65% for oral PDE5 inhibitors and closer to 50 to 60% for Caverject, with MUSE dropping to roughly 40 to 45% at one year.

A clinician at a high-volume andrology center would note: the most effective drug is the one the patient actually uses consistently at 18 months, not the one that works best in a controlled office setting.

Mechanism of Action: Why They Work Differently

Understanding why these two agents produce erections through entirely separate pathways helps predict who will respond to each one and for how long.

Sildenafil: PDE5 Inhibition Requires Intact Neural Signaling

Sildenafil is a selective phosphodiesterase type-5 (PDE5) inhibitor. Sexual stimulation releases nitric oxide (NO) from penile endothelium and nonadrenergic, noncholinergic (NANC) neurons. NO activates guanylate cyclase, raising cyclic GMP (cGMP), which relaxes cavernosal smooth muscle. Sildenafil blocks the breakdown of cGMP by PDE5, prolonging smooth muscle relaxation and penile engorgement [1].

The clinical implication: sildenafil requires a functional NO-cGMP axis. Men with complete pelvic nerve damage (radical prostatectomy without nerve-sparing, complete spinal cord injury) may generate insufficient NO regardless of PDE5 inhibitor dose, producing a primary non-response rate of 30 to 40% in that population.

Alprostadil: Direct Smooth Muscle Relaxation

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP2/EP3 receptors on cavernosal smooth muscle, directly elevating cyclic AMP (cAMP) independently of the NO pathway [2]. This mechanism explains alprostadil's utility in men where sildenafil fails: the drug bypasses the neural signaling step entirely.

Caverject (intracavernosal injection) delivers alprostadil directly into the corpus cavernosum, achieving local tissue concentrations that produce rigid erections in the majority of men regardless of neural status. MUSE (Medicated Urethral System for Erection) delivers the same molecule via a urethral pellet; absorption is less predictable, and efficacy is correspondingly lower, approximately 43% home-use response rate in the key MUSE trial versus 87% for intracavernosal delivery.

Long-Term Efficacy Trajectories: What Changes Over Years

Sildenafil: Stable Response With Progressive Disease as the Main Enemy

Among men who respond initially, sildenafil's effectiveness remains relatively stable over 2 to 3 years of continuous use. The primary reason for delayed failure is disease progression, not drug tolerance. Worsening endothelial dysfunction, new-onset diabetes, cardiovascular disease progression, or declining testosterone can erode the NO-cGMP axis that sildenafil depends on.

A cross-sectional analysis from a large Italian ED registry (N=1,200+) found that men on sildenafil for 36 months had IIEF erectile function domain scores approximately 1.2 points lower than at 12 months, a statistically detectable but clinically modest change [see below for HealthRX cohort data on dose escalation patterns over 24 months]. The implication is that most sildenafil users do not need dose escalation purely because of pharmacologic tolerance.

Alprostadil: Frontloaded Efficacy, Backend Dropouts

Alprostadil's per-injection efficacy does not meaningfully diminish with repeated use from a pharmacological standpoint. The issue is behavioral. Pain with injection, fibrosis at injection sites with repeated use, and the emotional and logistical burden of preparing and administering an injection before each sexual encounter create a progressive attrition curve.

Published follow-up data from the Linet trial extension showed that among men still using Caverject at 18 months, erection success rates per injection remained at approximately 72 to 74%. The drug worked for those who stayed. Those who left cited pain (37%), discomfort during erection (14%), and partner concerns (12%) as primary reasons.

MUSE shows an even steeper dropout pattern. A Cochrane-style systematic review of intraurethral alprostadil found that home-use efficacy declined from roughly 43 to 65% in the first 3 months to under 40% sustained use at 12 months, primarily because of urethral burning and the impracticality of the administration system for spontaneous sex.

Combination Use: When One Drug Is Not Enough

Some men with severe refractory ED use low-dose Caverject combined with sildenafil, a strategy supported by open-label case series. The rationale is additive: cAMP elevation from alprostadil plus cGMP elevation from sildenafil both converge on smooth muscle relaxation. This combination is not FDA-approved as a labeled combination regimen and should only be managed under physician supervision given the compounded risk of prolonged erection.

Comparing Side Effect Profiles Over Time

Side effects shape long-term durability as much as efficacy does.

Sildenafil Adverse Effects: Generally Tolerable

The most common sildenafil adverse effects are vasodilatory: headache (16% at 100 mg), flushing (10%), and nasal congestion (4%) in the Goldstein trial [1]. Visual disturbances (blue-tinged vision from PDE6 cross-reactivity) occur in approximately 3% of users. These effects tend to diminish over time in many users as they find their optimal dose, often 50 mg rather than 100 mg.

Serious adverse events are rare. Sildenafil is contraindicated with nitrates due to risk of severe hypotension. Men on alpha-blockers require dose adjustment. No cumulative organ toxicity from long-term sildenafil use has been identified in trials up to 4 years.

Alprostadil Adverse Effects: Local and Mechanistic

Alprostadil's adverse effects are local rather than systemic.

Caverject produces penile pain or aching in 29 to 37% of users across trials, relating to direct PGE1 receptor activation in penile tissue [2]. Prolonged erection (more than 4 hours) occurs in approximately 0.4 to 1% of injections and requires urgent medical attention. Penile fibrosis or Peyronie's-like plaque formation has been reported with long-term injection use at rates of 2 to 5% in the Linet extension.

MUSE causes urethral burning or discomfort in 32% of users and minor urethral bleeding in about 5%. Systemic hypotension from urethral absorption occurs in roughly 3% of patients.

These local effects directly drive the dropout curves described above. A man who experiences burning or penile pain on 3 to 4 consecutive attempts has a high probability of discontinuing regardless of how effective the drug is otherwise.

Who Should Use Which Drug: Patient Selection for Durability

Sildenafil Is the Right Starting Point for Most Men

Current American Urological Association (AUA) guidelines on erectile dysfunction recommend oral PDE5 inhibitors as first-line therapy for the majority of men with ED [see AUA 2018 ED Guideline at auanet.org]. Sildenafil generic (available from approximately $0.50, $2.00 per 20 mg tablet at compounding-friendly pharmacies) is accessible, effective, and does not require procedural training.

Men most likely to sustain a durable response to sildenafil long-term include those with psychogenic ED, mild to moderate vasculogenic ED, diabetes without complete neuropathy, and hypogonadism that is being concurrently treated with testosterone replacement therapy.

Alprostadil Is the Appropriate Second-Line or Adjunct Choice

Alprostadil enters the clinical picture when sildenafil fails at maximum tolerated dose (typically defined as two separate attempts at 100 mg), when sildenafil is contraindicated (concurrent nitrate use), or when the etiology of ED bypasses the NO pathway.

Men most likely to benefit from Caverject long-term include:

• Post-radical prostatectomy patients, especially those without nerve-sparing (sildenafil response rate as low as 20 to 30% in this group)
• Severe arterial insufficiency where NO synthesis is impaired even with PDE5 blockade
• Complete spinal cord injury above T6 where reflex erections are absent
• Men who have failed three or more PDE5 inhibitors at maximum dose

For post-prostatectomy patients specifically, early penile rehabilitation with alprostadil injections (beginning 4 to 8 weeks post-surgery) may preserve cavernosal smooth muscle and support eventual recovery of spontaneous erections, a concept supported by several small randomized trials though not yet by a definitive phase 3 study.

Switching From Sildenafil to Alprostadil: When and How

Switching is indicated when a patient has failed adequate trials of sildenafil (and ideally at least one other PDE5 inhibitor, such as tadalafil 20 mg, to confirm class failure rather than drug-specific failure).

The practical switching protocol used at most andrology centers involves:

1. Confirming true sildenafil failure: dose 100 mg, taken on empty stomach, with adequate sexual stimulation, on at least 4 to 6 attempts
2. Ruling out reversible causes: low testosterone (<300 ng/dL total T), uncontrolled diabetes (HbA1c >9%), untreated hypogonadism, or partner-related psychosexual factors
3. Initiating Caverject with in-office dose titration starting at 2.5 mcg, titrating by 2.5 to 5 mcg increments to find the minimum effective dose
4. Providing patient training on self-injection technique with a nurse or trained clinician
5. Scheduling a 4-week follow-up to assess home-use success and side effects

MUSE is generally reserved for men who refuse injection but have failed oral therapy, given its lower efficacy relative to Caverject.

Cost, Access, and Real-World Adherence Considerations

Sildenafil Generic Cost

Generic sildenafil became widely available in the United States after patent expiration of Viagra in 2017. Current retail pricing ranges from $0.50 to $3.00 per tablet depending on dose and pharmacy. Through telehealth platforms and compounding pharmacies, sildenafil 20 mg (off-label for ED; FDA-approved dose for pulmonary arterial hypertension) can be prescribed in quantities that reduce per-dose cost dramatically. Low cost directly supports long-term adherence.

Alprostadil Cost and Access Barriers

Caverject (Pfizer) and its branded equivalents carry significantly higher costs. A single Caverject Impulse kit retails at approximately $60, $150 per injection, though generic alprostadil formulations and compounded preparations are available at lower prices. MUSE suppositories retail at approximately $50, $100 per unit. The cost differential creates a real-world adherence disadvantage for alprostadil, particularly for men without comprehensive insurance coverage.

Beyond cost, the alprostadil injection system requires training, sterile technique, and psychological acceptance of self-injection, barriers that sildenafil's oral route simply does not carry.

Summary of Key Clinical Differences

| Parameter | Sildenafil Generic | Alprostadil (Caverject/MUSE) | |---|---|---| | Route | Oral | Intracavernosal injection / urethral pellet | | Onset | 30 to 60 min | 5 to 20 min | | Duration | 4 to 6 hours | 30 to 60 min | | Per-dose efficacy (office) | ~69% (100 mg) | ~87% (Caverject) | | 12-month continuation | ~55 to 65% | ~50 to 60% (Caverject), ~40 to 45% (MUSE) | | Primary dropout reason | Headache, flushing, cost | Penile pain, injection burden | | Requires intact NO pathway | Yes | No | | Priapism risk | Rare | <1% per injection | | FDA approval for ED | Yes | Yes | | Approximate cost per use | $0.50, $3.00 | $60, $150 (branded) |